Document is current
Any future updates will be listed below
-
Authors
Lin, Chujiao
Yang, Qiyuan
Guo, Dongsheng
Xie, Jun https://orcid.org/0000-0001-9565-1567
Yang, Yeon-Suk
Chaugule, Sachin https://orcid.org/0000-0001-6323-2034
DeSouza, Ngoc
Oh, Won-Taek https://orcid.org/0000-0003-1815-0851
Li, Rui https://orcid.org/0000-0003-3193-1396
Chen, Zhihao
John, Aijaz A.
Qiu, Qiang
Zhu, Lihua Julie https://orcid.org/0000-0001-7416-0590
Greenblatt, Matthew B. https://orcid.org/0000-0001-9794-8532
Ghosh, Sankar https://orcid.org/0000-0002-3227-0588
Li, Shaoguang https://orcid.org/0000-0002-8947-9614
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Haynes, Cole https://orcid.org/0000-0003-2110-5648
Emerson, Charles P.
Shim, Jae-Hyuck https://orcid.org/0000-0002-4947-3293
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR075585)
Pershing Square Foundation
- License Information
-
More Information
Article History
Received: 17 January 2022
Accepted: 27 October 2022
First Online: 11 November 2022
Competing interests
: G.G. and J.H.S. are co-founders of AAVAA Therapeutics and hold equity of this company. G.G. is a scientific co-founder of Voyager Therapeutics and Aspa Therapeutics Inc., and an inventor on patents with potential royalties licensed to other biopharmaceutical companies, in which they hold equity. Other authors declare no competing interests.
